These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22991868)

  • 41. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
    Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
    Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
    Oortwijn W; Mathijssen J; Banta D
    Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Conditional reimbursement: a tool to reduce uncertainty relating the value of medicines and reinforce their continuous evaluation in real-life].
    Bail JN
    Ann Pharm Fr; 2013 Sep; 71(5):326-9. PubMed ID: 24075702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?
    Kim AE; Choi DH; Chang J; Kim SH
    Clin Drug Investig; 2020 Dec; 40(12):1107-1113. PubMed ID: 33037566
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers.
    Carlson JJ; Gries KS; Yeung K; Sullivan SD; Garrison LP
    Appl Health Econ Health Policy; 2014 Jun; 12(3):231-8. PubMed ID: 24664994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Conditional pricing for innovative medicines in France: stop telling about risk-sharing!].
    Megerlin F
    Ann Pharm Fr; 2013 Sep; 71(5):291-301. PubMed ID: 24075700
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of a financial risk-sharing scheme on budget-impact estimations: a game-theoretic approach.
    Gavious A; Greenberg D; Hammerman A; Segev E
    Eur J Health Econ; 2014 Jun; 15(5):553-61. PubMed ID: 24326947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmaceutical risk-sharing agreements.
    Cook JP; Vernon JA; Manning R
    Pharmacoeconomics; 2008; 26(7):551-6. PubMed ID: 18563946
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NHS decision to deny drug to boy with severe autism was "fundamentally flawed".
    Dyer C
    BMJ; 2017 Aug; 358():j3822. PubMed ID: 28794057
    [No Abstract]   [Full Text] [Related]  

  • 51. Access with evidence development schemes: a framework for description and evaluation.
    McCabe CJ; Stafinski T; Edlin R; Menon D;
    Pharmacoeconomics; 2010; 28(2):143-52. PubMed ID: 20085390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Innovative patient access schemes for the adoption of new technology: risk-sharing agreements].
    Espín J; Oliva J; Rodríguez-Barrios JM
    Gac Sanit; 2010; 24(6):491-7. PubMed ID: 21074292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Performance-based risk-sharing agreements in renal care: current experience and future prospects.
    Drummond M; Federici C; Busink E; Apel C; Kendzia D; Brouwer W
    Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):197-209. PubMed ID: 33439090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk-sharing agreements, present and future.
    Gonçalves FR; Santos S; Silva C; Sousa G
    Ecancermedicalscience; 2018; 12():823. PubMed ID: 29743943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments.
    Antonanzas F; Juárez-Castelló C; Lorente R; Rodríguez-Ibeas R
    Pharmacoeconomics; 2019 Dec; 37(12):1469-1483. PubMed ID: 31535280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties.
    Towse A; Fenwick E
    Value Health; 2024 Aug; 27(8):1058-1065. PubMed ID: 38615938
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Innovating in pharmaceutical expenditure management: from payment per product to payment for health outcomes].
    Espín J
    Rev Esp Salud Publica; 2013; 87(4):303-6. PubMed ID: 24100769
    [No Abstract]   [Full Text] [Related]  

  • 58. Performance-based risk-sharing arrangements for devices and procedures in cardiac electrophysiology: an innovative perspective.
    Boriani G; Vitolo M; Svennberg E; Casado-Arroyo R; Merino JL; Leclercq C
    Europace; 2022 Oct; 24(10):1541-1547. PubMed ID: 35531864
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.